Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the company's strategic move to acquire Awakn Life Sciences. Tennyson outlined how this acquisition aligns with Solvonis' vision of becoming a leader in the treatment of addiction and mental health disorders. He emphasised the significant commercial opportunity presented by Awakn’s advanced clinical programs, particularly for alcohol use disorder and post-traumatic stress disorder.
"Awakn Life Sciences has a leading position in the research and development of therapeutics for the treatment of alcohol use disorder and post-traumatic stress disorder," Tennyson noted. Highlighting the groundbreaking results of Awakn’s AWKN-001 asset, he explained how clinical trials showed a jump from 2% to 86% sobriety among participants with severe alcohol use disorder.
The acquisition is valued at approximately £5 million and is expected to strengthen Solvonis' foothold in the UK biotechnology ecosystem, offering near to medium-term commercial opportunities. Tennyson expressed confidence in the strategic value of the deal, describing it as "pretty good value for Solvonis and Solvonis shareholders.
For more interviews and updates from leading companies, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content!
#SolvonisTherapeutics #AnthonyTennyson #AwaknLifeSciences #Biotechnology #AddictionTreatment #MentalHealth #AlcoholUseDisorder #InvestmentNews #ClinicalTrials #ProactiveInvestors